More than 70 years researching and improving health.
1946
Foundation of the Company
1981
Beginning of research into
low-molecular-weight heparins
1998
Launch of Bemiparin on the
Spanish market and start-up of
cooperations in Portugal
2002
Internationalization of ROVI® following
approval of Bemiparin outside Spain
2003
Increased International coverage
to 59 countries
2006
Construction of the Granada R&D&i
centre and plant
2007
Agreement with Laboratoires Servier for the
marketing of Corlentor®
2009
Strategic agreement with Merck
Sharp & Dhome (MSD)
2011
Agreement with MSD for the marketing of
Vitorin® and Absorcol®
2012
FDA certification of the
injectables plant
2013
Agreements to market products
from Novartis and Medice
2014
registration process for an
enoxaparin biosimilar with the EMA
2015
Adquisition of the new injectables plant
in San Sebastián de los Reyes.
Successful completion
of PRISMA-2 study.
Agreement with Astellas for the
marketing of Volutsa®
2016
Agrement with Novartis for the marketing
of Neparvis® and Orexigen for the
marketing of Mysimba®
2017
Successful completion of the
procedure to apply for authorization to market
an exoparin biosimilar in 26 UE countries